Reading The Tea Leaves For PD-1 Family In New Hematology Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nivolumab investigator, ASH presidential symposium speaker and translational biologist Margaret Shipp explains in an interview why PD-1 blockade might be better in Hodgkin lymphoma than PD-L1 inhibition, and contemplates the future in other blood diseases.